Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas

Annals of Neurology

Volumn 72, Issue 5, 2012, Pages 799-806

  Kunte, Hagen ^a   Busch, Markus A ^b   Trostdorf, Katrin ^a   Vollnberg, Bernd ^a   Harms, Lutz ^a   Mehta, Rupal I ^c   Castellani, Rudolf J ^c   Mandava, Pitchaiah ^d   Kent, Thomas A ^d   Simard, J Marc ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; BRAIN BIOPSY; BRAIN HEMORRHAGE; BRAIN NERVE CELL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANTIGENS, CD31; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN ISCHEMIA; CEREBRAL CORTEX; CEREBRAL HEMORRHAGE; DIABETES MELLITUS, TYPE 2; FEMALE; FUNCTIONAL LATERALITY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84871977989     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23680     Document Type: Article

References (31)

1. Khatri P, Wechsler LR, Broderick JP,. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007; 38: 431-440. (Pubitemid 46188260)
2. Lindley RI, Wardlaw JM, Sandercock PA, et al. Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis 2004; 13: 235-246. (Pubitemid 39470024)
3. Kerenyi L, Kardos L, Szasz J, et al. Factors influencing hemorrhagic transformation in ischemic stroke: A clinicopathological comparison. Eur J Neurol 2006; 13: 1251-1255. (Pubitemid 44581474)
4. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008; 39: 2249-2256.
5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
6. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-2011.
7. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
8. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59: 669-674.
9. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
10. Larrue V, von KR, del Zoppo GJ, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28: 957-960. (Pubitemid 27209140)
11. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441. (Pubitemid 32155231)
12. Yong M, Kaste M,. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 2008; 39: 2749-2755.
13. Park JH, Ko Y, Kim WJ, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology 2012; 78: 421-426.
14. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-276.
15. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6: 258-268. (Pubitemid 46228081)
16. Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006; 12: 433-440.
17. Simard JM, Yurovsky V, Tsymbalyuk N, et al. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009; 40: 604-609.
18. Simard JM, Tsymbalyuk N, Tsymbalyuk O, et al. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke 2010; 41: 531-537.
19. Simard JM, Geng Z, Silver FL, et al. Does inhibiting SUR1 complement rtPA in cerebral ischemia? Ann N Y Acad Sci 2012; (in press).
20. Simard JM, Woo SK, Tsymbalyuk N, et al. Glibenclamide-10 hour treatment window in a clinically-relevant model of stroke. Transl Stroke Res 2012; 3: 286-295.
21. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38: 2526-2530. (Pubitemid 47329632)
22. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251. (Pubitemid 28470336)
23. Mandava P, Kalkonde YV, Rochat RH, et al. A matching algorithm to address imbalances in study populations: Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial. Stroke 2010; 41: 765-770.
24. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011; 68: 1245-1251.
25. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC,. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012; 12: 148-158.
26. Martini SR, Kent TA,. Hyperglycemia in acute ischemic stroke: A vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-451.
27. Elgebaly MM, Ogbi S, Li W, et al. Neurovascular injury in acute hyperglycemia and diabetes: A comparative analysis in experimental stroke. Transl Stroke Res 2011; 2: 391-398.
28. Favilla CG, Mullen MT, Ali M, et al. Sulfonylurea use before stroke does not influence outcome. Stroke 2011; 42: 710-715.
29. Simard JM, Kent TA, Kunte H,. Letter by Simard et al regarding article, "Sulfonylurea use before stroke does not influence outcome." Stroke 2011; 42: e409.
30. Arboix A,. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke. Stroke 2007; 38: 2413-2414. (Pubitemid 47329615)
31. Da Silva-Santos JE, Santos-Silva MC, Cunha FQ, et al. The role of ATP-sensitive potassium channels in neutrophil migration and plasma exudation. J Pharmacol Exp Ther 2002; 300: 946-951. (Pubitemid 34165000)